查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1908189

抗菌藥物抗藥性診斷市場規模、佔有率和趨勢分析報告：按技術、病原體、最終用途、地區和細分市場預測（2026-2033 年）

Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report By Technology, By Pathogen, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

抗菌藥物抗藥性診斷市場概覽

全球抗生素抗藥性診斷市場預計到 2025 年將價值 34.2 億美元，預計到 2033 年將達到 46.8 億美元。

預計從 2026 年到 2033 年，該市場將以 4.08% 的複合年成長率成長。肺炎鏈球菌、抗困難梭狀芽孢桿菌葡萄球菌 (MRSA) 和艱難梭菌等病原體的高盛行率，以及抗菌素抗藥性 (AMR)感染疾病的增加，是市場擴張的主要促進因素。

據美國疾病管制與預防中心 (CDC) 稱，美國每年約有 280 萬例抗菌藥物抗藥性 (AMR ) 美國；美國藥典委員會 (USP) 報告稱，AMR 每年在全球造成約 70 萬人死亡——如果微生物感染疾病得不到正確診斷和治療，到 2050 年，這一數字可能達到 1000 萬。

預計對先進、精準診斷解決方案的監管核准不斷增加將支撐市場需求的成長。例如，2021年10月，Hologic公司在歐洲推出了Mobidiag Oy公司的全自動分子診斷系統Novodiag。該系統整合了微陣列和即時PCR技術，可按需檢測抗菌素抗藥性和感染疾病，並從單一檢體中識別多種病原體。同月，OpGen公司獲得了美國FDA的510(k)許可，可以銷售其Acuitas AMR基因檢測板。此檢測板可檢測多種病原體中28種抗菌素抗藥性基因標記，幫助醫療專業人員管理病菌感染。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 抗菌素抗藥性診斷市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 抗菌素抗藥性診斷市場分析工具
    • 產業分析：波特五力模型
    • PESTEL 分析

第4章：抗菌素抗藥性診斷市場：依技術、估算與趨勢分析

  • 抗菌藥物抗藥性診斷市場：技術變革分析
  • 抗菌藥物抗藥性診斷市場：技術展望
  • 市場規模、預測與趨勢分析（2021-2033）
  • 微生物培養
  • 免疫檢測
    • PCR
    • 下一代定序（NGS）
    • 質譜分析
    • 快速檢測/照護現場
    • 其他

第5章：按病原體分類的抗菌素抗藥性診斷市場：估算與趨勢分析

  • 抗菌素抗藥性診斷市場：病原體變異分析
  • 抗菌藥物抗藥性診斷市場：病原體特異性展望
  • 市場規模、預測與趨勢分析（2021-2033）
  • 抗藥性肺炎鏈球菌 (DRSP)
  • 抗藥性彎曲桿菌（DRC）
  • 困難梭狀芽孢桿菌（CD）
  • 抗藥性金黃色葡萄球菌（MRSA）
  • 抗藥性淋病奈瑟菌（DRNG）
  • 抗藥性沙門氏菌（DRNTS）
  • 其他

第6章：抗菌素抗藥性診斷市場按最終用途分類、估算和趨勢分析

  • 抗菌素抗藥性診斷市場：終端用途差異分析
  • 抗菌藥物抗藥性診斷市場：終端用戶展望
  • 市場規模、預測與趨勢分析（2021-2033）
  • 醫院
  • 診斷實驗室
  • 製藥和生物技術公司
  • 其他

第7章：抗菌素抗藥性診斷市場：區域、估算與趨勢分析

  • 區域儀錶板
  • 市場規模及預測趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
    • 葡萄牙
    • 土耳其
    • 瑞士
    • 比利時
    • 荷蘭
    • ROE
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 馬來西亞
    • 印尼
    • 越南
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 秘魯
    • 厄瓜多
    • 其他拉丁美洲國家
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 市場參與企業分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 企業市場占有率分析（2025）
  • 主要企業簡介
    • bioMerieux
    • F. Hoffmann-La Roche Ltd
    • Abbott
    • BD
    • Danaher
    • Accelerate Diagnostics, Inc.
    • Molsid
    • Vela Diagnostics
    • Visby Medical, Inc.
    • Hologic, Inc.
    • OpGen.
    • Seegene Inc
    • EliTechGroup
    • CERTEST BIOTEC
Product Code: GVR-4-68039-990-4

Antimicrobial Resistance Diagnostics Market Summary

The global antimicrobial resistance diagnostics market size was estimated at USD 3.42 billion in 2025 and is expected to reach USD 4.68 billion by 2033, growing at a CAGR of 4.08% from 2026 to 2033. The high prevalence of pathogens such as Streptococcus pneumoniae, MRSA, and C. difficile, along with the increasing number of antimicrobial-resistant (AMR) infections, is significantly driving market expansion.

According to the CDC, approximately 2.8 million AMR cases occur annually in the U.S., and the U.S. Pharmacopeial Convention reports that AMR leads to around 700,000 deaths globally each year. This number could potentially rise to 10 million by 2050 if proper diagnosis and treatment of microbial infections are not implemented.

The rise in regulatory approvals for advanced and accurate diagnostic solutions is expected to meet the growing demand in the market. For example, in October 2021, Hologic, Inc. launched the fully automated Novodiag molecular diagnostic system from Mobidiag Oy in Europe. This system, which integrates microarray and real-time PCR technology, enables on-demand testing for antimicrobial resistance and infectious diseases, identifying multiple pathogens from a single sample. Additionally, in the same month, OpGen, Inc. received 510(k) clearance from the U.S. FDA to market its Acuitas AMR Gene Panel. This panel tests for 28 genetic antimicrobial resistance markers across various pathogens, aiding healthcare providers in managing resistant bacterial infections.

Global Antimicrobial Resistance Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the antimicrobial resistance diagnostics market report based on technology, pathogen, end use, and region:

  • Technology Outlook (Revenue, USD Million; 2021 - 2033)
  • Microbiology Culture
  • Immunoassay
  • PCR
  • NGS
  • Mass Spectrometry
  • Rapid & Point of Care
  • Others
  • Pathogen Outlook (Revenue, USD Million; 2021 - 2033)
  • Drug Resistant Streptococcus Pneumoniae (DRSP)
  • Drug Resistant Campylobacter (DRC)
  • Clostridium Difficile (CD)
  • Methicillin Resistant Staphylococcus Aureus (MRSA)
  • Drug Resistant Neisseria Gonorrhoeae (DRNG)
  • Drug Resistant Salmonella (DRNTS)
  • Others
  • End Use Outlook (Revenue, USD Million; 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Others
  • Regional Outlook (Revenue, USD Million; 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Norway
    • Denmark
    • Sweden
    • Norway
    • Portugal
    • Turkey
    • Switzerland
    • Belgium
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
    • Malaysia
    • Indonesia
    • Vietnam
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Colombia
    • Peru
    • Ecuador
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Pathogen
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Antimicrobial Resistance Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in risk of developing drug-resistant bacterial infections
      • 3.2.1.2. Introduction of novel technologies to diagnose AMR infections
      • 3.2.1.3. Favorable government initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
  • 3.3. Antimicrobial Resistance Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Antimicrobial Resistance Diagnostics Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Antimicrobial Resistance Diagnostics Market: Technology Movement Analysis
  • 4.3. Antimicrobial Resistance Diagnostics Market by Technology Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Microbiology Culture
    • 4.5.1. Microbiology Culture Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Immunoassay
    • 4.6.1. Immunoassay Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. PCR
      • 4.6.2.1. PCR Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. NGS
      • 4.6.3.1. NGS Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Mass Spectrometry
      • 4.6.4.1. Mass Spectrometry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.5. Rapid & Point of Care
      • 4.6.5.1. Rapid & Point of Care Assays Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Antimicrobial Resistance Diagnostics Market: Pathogen Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Antimicrobial Resistance Diagnostics Market: Pathogen Movement Analysis
  • 5.3. Antimicrobial Resistance Diagnostics Market by Pathogen Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Drug Resistant Streptococcus Pneumoniae (DRSP)
    • 5.5.1. Drug Resistant Streptococcus Pneumoniae (DRSP) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Drug Resistant Campylobacter (DRC)
    • 5.6.1. Drug Resistant Campylobacter (DRC) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Clostridium Difficile (CD)
    • 5.7.1. Clostridium Difficile (CD) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Methicillin Resistant Staphylococcus Aureus (MRSA)
    • 5.8.1. Methicillin Resistant Staphylococcus Aureus (MRSA) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Drug Resistant Neisseria Gonorrhoeae (DRNG)
    • 5.9.1. Drug Resistant Neisseria Gonorrhoeae (DRNG) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.10. Drug Resistant Salmonella (DRNTS)
    • 5.10.1. Drug Resistant Salmonella (DRNTS) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.11. Others
    • 5.11.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Antimicrobial Resistance Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Antimicrobial Resistance Diagnostics Market: End Use Movement Analysis
  • 6.3. Antimicrobial Resistance Diagnostics Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Pharmaceutical & Biotechnology Companies
    • 6.7.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Antimicrobial Resistance Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.9. Portugal
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Regulatory framework/ reimbursement structure
      • 7.4.9.3. Competitive scenario
      • 7.4.9.4. Portugal market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.10. Turkey
      • 7.4.10.1. Key country dynamics
      • 7.4.10.2. Regulatory framework/ reimbursement structure
      • 7.4.10.3. Competitive scenario
      • 7.4.10.4. Turkey market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.11. Switzerland
      • 7.4.11.1. Key country dynamics
      • 7.4.11.2. Regulatory framework/ reimbursement structure
      • 7.4.11.3. Competitive scenario
      • 7.4.11.4. Switzerland market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.12. Belgium
      • 7.4.12.1. Key country dynamics
      • 7.4.12.2. Regulatory framework/ reimbursement structure
      • 7.4.12.3. Competitive scenario
      • 7.4.12.4. Belgium market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.13. Netherlands
      • 7.4.13.1. Key country dynamics
      • 7.4.13.2. Regulatory framework/ reimbursement structure
      • 7.4.13.3. Competitive scenario
      • 7.4.13.4. Netherlands market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.14. ROE
      • 7.4.14.1. Key country dynamics
      • 7.4.14.2. Regulatory framework/ reimbursement structure
      • 7.4.14.3. Competitive scenario
      • 7.4.14.4. ROE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.7. Malaysia
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework/ reimbursement structure
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Malaysia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.8. Indonesia
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework/ reimbursement structure
      • 7.5.8.3. Competitive scenario
      • 7.5.8.4. Indonesia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.9. Vietnam
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Regulatory framework/ reimbursement structure
      • 7.5.9.3. Competitive scenario
      • 7.5.9.4. Vietnam market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.10. Rest of APAC
      • 7.5.10.1. Key country dynamics
      • 7.5.10.2. Regulatory framework/ reimbursement structure
      • 7.5.10.3. Competitive scenario
      • 7.5.10.4. ROE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. Colombia
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Colombia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Peru
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Peru market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Ecuador
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Ecuador market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Rest of Latin America
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Rest of Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2025
  • 8.4. Key Company Profiles
    • 8.4.1. bioMerieux
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. F. Hoffmann - La Roche Ltd
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Abbott
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. BD
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Danaher
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Accelerate Diagnostics, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Molsid
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Vela Diagnostics
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Visby Medical, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Hologic, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. OpGen.
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Seegene Inc
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. EliTechGroup
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Product benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. CERTEST BIOTEC
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Product benchmarking
      • 8.4.14.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 4 Global antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 5 Global antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 6 North America Antimicrobial Resistance Diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 7 North America antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 8 North America antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 9 North America antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 10 US antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 11 US antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 12 US antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 13 Mexico antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 14 Mexico antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 15 Mexico antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Canada antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 17 Canada antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 18 Canada antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 19 Europe antimicrobial resistance diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 20 Europe antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 21 Europe antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 22 Europe antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 23 UK antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 24 UK antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 25 UK antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 26 Germany antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 27 Germany antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 28 Germany antimicrobial resistance diagnostics market, by End Use 2021 - 2033 (USD Million)
  • Table 29 France antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 30 France antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 31 France antimicrobial resistance diagnostics market, by End Use 2021 - 2033 (USD Million)
  • Table 32 Italy antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 33 Italy antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 34 Italy antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 35 Spain antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 36 Spain antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 37 Spain antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 38 Denmark antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 39 Denmark antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 40 Denmark antimicrobial resistance diagnostics market, by End Use 2021 - 2033 (USD Million)
  • Table 41 Norway antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 42 Norway antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 43 Norway antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 44 Sweden antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 45 Sweden antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 46 Sweden antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 47 Portugal antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 48 Portugal antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 49 Portugal antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 50 Belgium antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 51 Belgium antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 52 Belgium antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 53 Turkey antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 54 Turkey antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 55 Turkey antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 56 Switzerland antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 57 Switzerland antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 58 Switzerland antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 59 Netherlands antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 60 Netherlands antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 61 Netherlands antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 62 ROE antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 63 ROE antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific antimicrobial resistance diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 67 Asia Pacific antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 68 Japan antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 69 Japan antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 70 Japan antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 71 China antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 72 China antimicrobial resistance diagnostics market, by Pathogen 2021 - 2033 (USD Million)
  • Table 73 China antimicrobial resistance diagnostics market, by End Use 2021 - 2033 (USD Million)
  • Table 74 India antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 75 India antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 76 India antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 77 Australia antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 78 Australia antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 79 Australia antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 80 South Korea antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 81 South Korea antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 82 South Korea antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 83 Thailand antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 84 Thailand antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 85 Thailand antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 86 Malaysia antimicrobial resistance diagnostics market, by Product, 2021 - 2033 (USD Million)
  • Table 87 Malaysia antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 88 Malaysia antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 89 Indonesia antimicrobial resistance diagnostics market, by Product, 2021 - 2033 (USD Million)
  • Table 90 Indonesia antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 91 Indonesia antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 92 Vietnam antimicrobial resistance diagnostics market, by Product, 2021 - 2033 (USD Million)
  • Table 93 Vietnam antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 94 Vietnam antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 95 Rest of APAC antimicrobial resistance diagnostics market, by Product, 2021 - 2033 (USD Million)
  • Table 96 Rest of APAC antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 97 Rest of APAC antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 98 Latin America antimicrobial resistance diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 99 Latin America antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 100 Latin America antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 101 Latin America antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 102 Brazil antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 103 Brazil antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 104 Brazil antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 105 Argentina antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 106 Argentina antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 107 Argentina antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 108 Colombia antimicrobial resistance diagnostics market, by Product, 2021 - 2033 (USD Million)
  • Table 109 Colombia antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 110 Colombia antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 111 Peru antimicrobial resistance diagnostics market, by Product, 2021 - 2033 (USD Million)
  • Table 112 Peru antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 113 Peru antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 114 Ecuador antimicrobial resistance diagnostics market, by Product, 2021 - 2033 (USD Million)
  • Table 115 Ecuador antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 116 Ecuador antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 117 Middle East & Africa antimicrobial resistance diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 118 Middle East & Africa antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 119 Middle East & Africa antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 120 Middle East & Africa antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 121 South Africa antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 122 South Africa antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 123 South Africa antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 124 Saudi Arabia antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 125 Saudi Arabia antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 126 Saudi Arabia antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 127 UAE antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 128 UAE antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 129 UAE antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million)
  • Table 130 Kuwait antimicrobial resistance diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 131 Kuwait antimicrobial resistance diagnostics market, by Pathogen, 2021 - 2033 (USD Million)
  • Table 132 Kuwait antimicrobial resistance diagnostics market, by End Use, 2021 - 2033 (USD Million

List of Figures

  • Fig 1 Information procurement
  • Fig 2 Primary research pattern
  • Fig 3 Market research approaches
  • Fig 4 Value chain-based sizing & forecasting
  • Fig 5 Market formulation & validation
  • Fig 6 Antimicrobial Resistance Diagnostics market segmentation
  • Fig 7 Market driver analysis (current & future impact)
  • Fig 8 Market restraint analysis (current & future impact)
  • Fig 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig 10 Porter's five forces analysis
  • Fig 11 Antimicrobial resistance diagnostics market, Technology outlook key takeaways 2025 & 2033 (USD Million)
  • Fig 12 Antimicrobial resistance diagnostics market: Pathogen movement analysis 2025 & 2033 (USD Million)
  • Fig 13 Antimicrobial resistance diagnostics market: end use movement analysis 2025 & 2033 (USD Million)
  • Fig 14 Microbiology Culture market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 15 Immunoassay market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 16 PCR market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 17 NGS market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 18 Mass Spectrometry market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 19 Rapid & Point of Care market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 20 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 21 Drug Resistant Streptococcus Pneumoniae market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 22 Drug Resistant Campylobacter market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 23 Clostridium Difficile market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 24 Methicillin Resistant Staphylococcus Aureus market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 25 Drug Resistant Neisseria Gonorrhoeae market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 26 Drug Resistant Salmonella market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 27 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 28 Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 29 Diagnostic Laboratories market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 30 Pharmaceutical & Biotechnology Companies market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 31 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 32 North America antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 33 US antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 34 US antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 35 Canada antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 36 Mexico antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 37 Europe antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 38 UK antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 39 Germany antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 40 France antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 41 Spain antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 42 Italy antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 43 Belgium antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 44 Portugal antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 45 Netherlands antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million
  • Fig 46 Turkey antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million
  • Fig 47 Switzerland antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million
  • Fig 48 Asia Pacific antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 49 China antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 50 Japan antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 51 India antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 52 South Korea antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 53 Australia antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 54 Thailand antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 55 Malaysia antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 56 Indonesia antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 57 Vietnam antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 58 ROE antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 59 Latin America antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 60 Brazil antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 61 Argentina antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 62 Peru antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 63 Colombia antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 64 Ecuador antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 65 Middle East and Africa antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 66 South Africa antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 67 Saudi Arabia antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 68 UAE antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 69 Kuwait antimicrobial resistance diagnostics market estimates and forecasts, 2021 - 2033 (USD Million
  • Fig 70 List of key emerging company's/Allergen disruptors/innovators